INTRODUCTION
The prevalence of diabetes continues to rise each year. In 2011, it was estimated that approximately 366 million people-7% of the world's population-had diabetes, with approximately 80% of these people living in developing countries [1] . The expectation is that these numbers will increase to 552 million adults (8.3% of the world's population) by 2030 [1] . Complications due to diabetes are also a growing public health problem. One of the most common complications of diabetes is diabetic foot ulcers (DFUs). DFUs are complex chronic wounds that have a major long-term impact on the morbidity, mortality and quality of patients' lives [2, 3] . Individuals who develop DFUs are at greater risk of premature death, myocardial infarction and fatal stroke than those without a history of this complication [4] . Approximately 25% of people with diabetes will develop a lower extremity ulcer over time [5, 6] . The treatment of these wounds remains challenging as they are often slow to heal and frequently reoccur. The poor prognosis of DFUs is attributed to those conditions often associated with diabetes, such as peripheral vascular diseases, neuropathy and poor blood glucose control. The delayed healing of ulcers increases the risk for severe wound infection and amputation [7, 8] ; approximately half of all people undergoing non-traumatic amputations are diagnosed with diabetes [9] , with studies showing that up to 88% of all diabetes-related amputations are preceded by a foot ulcer [10, 11] . Amputation can in turn increase morbidity and healthcare costs while at the same time reduce an individual's productivity and quality of life. Moreover, the mortality following amputation increases with level of amputation [12] . A 5-year mortality rate is very high among patients with any amputation (major and minor combined), ranging from 53 to 100%, and in patients with major amputation, it ranges from 52 to 80% [13] . Mortality following amputation is comparable to many types of cancer [10] . Therefore, any treatment that can reduce amputation rates is more than welcome. The main goal of treating DFUs is to promote a rapid and complete healing in order to reduce the risk of infection, amputation and other form of related complications.
Moist dressings, debridement, wound offloading and infection control are standard therapy or standard of care (SOC) in the management of DFUs. Standard therapy is commonly used in many clinic centers across the world. The Wound Healing Society guidelines recommend consideration of advanced wound therapies if the diabetic ulcer does not decrease in size by 40% or more after 4 weeks of standard therapy [14] . However, the guidelines of the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine recommend adjunctive wound therapy if DFUs fail to improve (reduction of [50% wound area) after a minimum of 4 weeks of standard wound therapy [15] .
Processed human amnion/chorion membrane (cryopreserved, dehydrated or acellular) is considered to be an adjunctive wound therapy. Several studies have recently shown its effectiveness in diabetic wound healing [16, 17] . It promotes wound closure, resulting in a more consistent and faster healing of chronic DFUs when compared with standard therapy alone [18] . In fact, many studies have shown human amniotic membrane has properties that enhance healing. The PURION Ò processed dehydrated human amnion/chorion membrane (dHACM) retains biologically active growth factors and regulatory factors that are in part responsible for its clinical effectiveness in wound healing [19] . dHACM can stimulate diabetic adipose-derived stem cells (ADSCs) to migrate, proliferate and alter cytokine expression, suggesting that ADSCs may respond to dHACM to accelerate diabetic wound healing [20] . Cell-seeded acellular amniotic membrane has the potential to deliver autologous or allogeneic cells to treat a variety of conditions, including DFUs, corneal defect and severe skin burns [21] . Cryopreserved human amniotic membrane retains all of its native human amniotic membrane components, including viable endogenous cells that can enhance angiogenic activity in chronic wounds [22] . Amnion products are now available and can be found in different forms according to their components or processing methods [23] .
To further evaluate the efficacy and time sensitivity of human amnion/chorion membrane (HACM) allografts in patients with chronic DFUs, we performed a systematic review and meta-analysis to compare HACM ? SOC with SOC alone (HACM ? SOC vs. SOC alone), since there has never been any systematic review and meta-analysis of this topic.
METHODS

Study Selection and Data Extraction
The PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for relevant papers up to and including 10 April 2017. To identify all relevant studies, we used the search terms ''diabetic foot ulcers'' OR ''diabetic foot'' AND ''amniotic membrane'' OR ''amnion'' OR ''bioimplant dressing'' OR ''Grafix'' OR ''EpiFix'' AND ''standard therapy ''or ''standard of care.''
The eligibility criteria were: (1) prospective randomized control trials (RCTs); (2) studies comparing human amniotic membrane ? standard therapy versus standard therapy in patients with DFUs; (3) studies in which an assessment of wound healing rates was conducted at least within a period of no less than 4 weeks and no more than 12 weeks; (4) studies published in English; (5) studies with complete outcome. Studies were excluded when they did not fulfill these inclusion criteria.
A flowchart of the study selection is shown in Fig. 1 .
To be able to focus on the efficacy and time sensitivity of HACM ? SOC treatment, the outcomes of the seven studies included in our analysis were subdivided into three groups: (1) assessment at 4 weeks [24, 25] ; (2) assessment at 6 weeks [24] [25] [26] [27] [28] ; (3) assessment at 12 weeks [26, 29, 30] .
The three groups of assessment time points with respect to incomplete healing are shown in a forest plot in Fig. 2 . In each group, we compared unhealed ulcers using two interventions (HACM ? SOC and SOC alone).
Study Quality and Risk of Bias Assessment
All of the authors worked independently to search for and assess studies for their methodological quality. The Cochrane Collaboration's tool for assessing the risk of bias was used. This tool includes seven entries: random sequence generation, allocation concealment, blinding of participants, blinding of personnel, blinding of outcome assessor, incomplete outcome data and selective reporting. If one study had more than two ''high-risk'' entries, it was considered to be of low quality; otherwise, it was considered to be of high quality [31] . Any disagreement in the assessment of studies was resolved by consensus and, if necessary, Qing Feng Cheng and Qi Fu Li were consulted.
Statistical Analysis
Odds ratios (ORs) with 95% of confidence interval (CIs) were calculated to assess the effect of dichotomous data. I 2 and P values were calculated to assess the heterogeneity among studies (I 2 [50% and/or P\0.1 were considered to be statistically significant). The ORs were pooled using only a random effects model to calculate a more conservative result. When ORs Fig. 1 Flowchart of study selection were \1, the intervention was associated with lower risk on outcome; when ORs were [1, the intervention was more associated with higher risk on outcome. Subgroup analyses were performed according to the time of wound healing assessment. The subgroup differences were also tested. Sensitivity analyses were performed on the high-quality studies. P\0.05 was considered to indicate a statistically significant difference in outcome between HACM ? SOC and SOC alone. Review Manager version 5.3 software was employed for the statistical analyses.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
A total of 352 published studies were retrieved from the four databases, among which 47 were potentially relevant. Further study of these 47 potentially relevant papers revealed that 40 were overlapping studies and subsequently excluded from the analysis. Seven studies were ultimately were included in the meta-analysis [24] [25] [26] [27] [28] [29] [30] (Fig. 1) , of which six were conducted in USA and one was conducted in Iran. The studies and the properties of the commercial amniotic membrane products are summarized in Tables 1  and 2 .
Study Characteristics
In all studies, minimum management consisted of standard care of the wound (SOC). In No signs of infections the intervention groups, treatment with amniotic membrane was added to the therapeutic regimen. As result, data comparing amniotic membrane ? standard therapy versus standard therapy alone were considered ( Table 3) . As in the RCT of Snyder et al. [28] , we considered per protocol subjects because eight patients were withdrawn at an early stage (4 in each group).
Patients Characteristics
The baseline characteristics regarding age, gender, body mass index, percentage glycated hemoglobin, ankle brachial index, ulcer type, ulcer location, ulcer etiology, wound surface area, wound duration, infection and Wagner grade of patients were comparable between the intervention group (HACM ? SOC) and control group (SOC). There were no statistically 
Risk of Bias
Risk of bias assessment for each study is summarized in Table 4 . All included studies were of high quality.
Outcome
There were far fewer unhealed wounds in patients receiving amniotic membrane ? SOC treatment than in those receiving SOC alone. The overall effect in the group assessed at 4 weeks was Z = 4.14 (P\0.0001; OR 0.05; 95% CI 0.01-0.21). The overall effect in the group assessed at 6 weeks was Z = 4.28 (P\0.0001; OR 0.07; 95% CI 0.02-0.23). The overall effect in the group assessed at 12 weeks was Z = 4.96 (P\0.00001; OR 0.10; 95% CI 0.04-0.24. The heterogeneity in each subgroup was not statistically significant. In the subgroup assessed at 4 weeks, I 2 = 0% (P = 0.32); in the subgroup assessed at 6 weeks, I 2 = 47% (P = 0.11); in the subgroup assessed at 12 weeks, I 2 = 24% (P = 0.27).
In the test for subgroup differences, the heterogeneity was also not statistically significant. For the subgroup differences, I 2 = 0% (P = 0.76)
DISCUSSION
The results of this systematic review and meta-analysis show that amniotic membrane is beneficial for treating chronic DFUs when it is In all subgroups assessed, the efficacy of treatment with amniotic membrane was remarkable. The overall effect of incomplete wound healing between the intervention group and control group at 4, 6 and 12 weeks was Z = 4.14 (P\0.0001; OR 0.05; 95% CI 0.01-0.21), Z = 4.28 (P\0.0001; OR 0.07; 95% CI 0.02-0.23) and Z = 4.96 (P\0.00001; OR 0.10; 95% CI 0.04-0.24), respectively. In all three subgroups, the odds ratio and their standard deviation were \1, indicating that the incomplete healing outcomes are less associated with amniotic membrane ? SOC. In addition, in all the groups, the P value was\0.05. There is statistically significant difference between the intervention group (HACM ? SOC) and the control group (SOC). Incomplete outcome Low risk All randomized patients were followed until the end
Selective reporting Low risk Expected endpoint
Those results support previous findings that the amniotic membrane ? SOC treatment has a greater efficacy for wound healing than SOC alone. This combined treatment strategy allows wound closure faster than the SOC, which is in turn beneficial for the treatment of DFUs. In fact, the main goal of DFU treatment is to promote rapid and complete healing in order to reduce the risk for infection, amputation and other forms of related complications. The use of placental membranes for wound healing was first reported towards the middle of the last century [32] . Initially, the amnion was predominantly viewed as a treatment for burns, and reports on its use in the treatment of chronic ulcers was limited to a few cases and studies [33] [34] [35] . However, more recently it has been shown that the human amnion/chorion membrane is beneficial for treating and healing DFUs [24] [25] [26] [27] [28] [29] [30] .
The intrinsic properties of the amnion explain its efficacy in enhancing the healing of chronic DFUs. HACM has the potential to positively affect four distinct and pivotal physiological processes closely involved in wound healing, namely cell proliferation, inflammation, metalloproteinase activity and recruitment of progenitor cells [19] . HACM also has the potential to promote revascularization and tissue healing within poorly vascularized, non-healing wounds as it contains angiogenic growth factor that retains biological activity [36] . The low immunogenicity of HACM also permits its allogeneic use. It acts as a physical barrier against bacterial contamination and also creates the moist environment required for healing. Furthermore, it reduces pain and has anti-inflammatory, anti-fibrotic, and anti-microbial activities that are beneficial to wound healing [22, 37] .
Our assessment of unhealed wounds showed no statistical difference in unhealed wounds at the 4-week and 6-week time points (Z = 4.14; P\0.0001; OR 0.05, 95% CI 0.01-0.21 vs. Z = 4.28; P\0.0001; OR 0.07; 95% CI 0.02-0.23, respectively). There was a statistical difference at 12 weeks (Z = 4.96; P\0.00001; OR 0.10; 95% CI 0.04-0.24. Thus, the sensitivity to the intervention at 4 weeks was almost the same as that at 6 weeks but it was statistically different from that at 12 weeks. Our analysis reveals that when using HACM as adjuvant therapy in patients with DFUs, the optimal times to assess healing should be 4 weeks and 12 weeks. This result correlates positively with previous findings. It should be noted that when SOC alone is used as treatment, a wound that does not decrease in area by C40% at 4 weeks has very little chance of healing at 12 weeks [14] ; therefore, other treatments should be considered. Early decrease in size indicates a good prognosis. In fact, 4 weeks of observation is a robust predictor of healing at 12 weeks [38] .
In addition, amniotic membrane products are relatively inexpensive and even more effective [29] . As such, such products should be useful in low-income countries.
The studies included in the meta-analysis have a number of limitations. Although we observed a great efficacy of amniotic membrane treatment in these studies, it cannot be used alone. The SOC must be accompanied by at least debridement and dressing changes. Secondly, most of our studies assessed the amniotic membrane effect in clinically uninfected wounds, with the only exception being the study of Mohajeri-Tehrani et al. [27] in which some clinically infected wounds were included. As HACM has antibacterial properties, more RCTs are needed to assess the efficacy of this treatment in clinically infected wounds. It is not always straightforward to rule out infections in initially clinically uninfected wounds of diabetic patients. Finally, the number of studies and the sample sizes were not sufficiently large, which can increase biases.
CONCLUSIONS
This systematic review and meta-analysis included studies conducted in different countries. The final results demonstrate that human amnion/chorion membrane ? standard of care heals DFUs significantly faster than SOC alone. Based on the current evidence of this meta-analysis and previous findings, we suggest that when HACM is used to treat patients with DFUs, the optimal times to assess healing should be 4 weeks and 12 weeks. Further, large-sized studies or RCTs are still needed to verify our findings and assess healing in infected DFUs.
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